Anticoagulation in Nephrotic Syndrome with Very Low Albumin

Introduction to Anticoagulation

The Kidney Disease: Improving Global Outcomes (KDIGO) guidelines recommend prophylactic anticoagulation in patients with nephrotic syndrome and very low albumin, as it creates a severe hypercoagulable state that significantly increases the risk of life-threatening thromboembolic events, including pulmonary embolism, deep vein thrombosis, and renal vein thrombosis 1

Loss of antithrombotic proteins in urine, including antithrombin III, protein C, and protein S, reduces the body's natural anticoagulant defenses 1

According to KDIGO 2021 guidelines, prophylactic anticoagulation should be employed when serum albumin is <20-25 g/L PLUS any of the following additional risk factors: proteinuria >10 g/day 2, body mass index >35 kg/m² 2, heart failure (NYHA class III or IV) 2, recent orthopedic or abdominal surgery 2, prolonged immobilization 2, or membranous glomerulonephritis (particularly high thrombotic risk) 1

Warfarin remains the anticoagulant of choice for nephrotic syndrome due to extensive long-term experience and predictable pharmacokinetics despite hypoalbuminemia 1, 2
Initiation protocol includes starting with intravenous unfractionated heparin or subcutaneous low-molecular-weight heparin as bridging therapy, with higher than usual heparin dosing required due to urinary loss of antithrombin III 1, 2
Transition to warfarin with target INR 2-3, and monitor INR frequently due to fluctuating albumin levels 1, 2

Before initiating anticoagulation, carefully evaluate for absolute contraindications, including falls risk/frailty, prior gastrointestinal bleeding, bleeding diathesis, CNS lesions, and patient adherence 1, 2

The decision favors anticoagulation when serum albumin <20-25 g/L, membranous nephropathy is suspected or confirmed, patient has additional risk factors, and no absolute bleeding contraindications exist 1